Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brachytherapy seeds work on prostate cancer:

This article was originally published in Clinica

Executive Summary

Brachytherapy using Theragenics' radioactive seed implants performed as well as or better than traditional treatments for prostate cancer such as radical prostatectomy and external beam radiation, according to a nine-year US study. Some 83.5% of the 230 stage I and II patients treated with the company's TheraSeed - palladium 103 - implants were cancer-free at nine years, researchers from the Seattle Prostate Institute in Washington reported in the March issue of the International Journal of Radiation Oncology, Biology and Physics. Only 3% of patients experienced prostate cancer recurrence, said Theragenics of Buford, Georgia.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT075859

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel